https://mindmedicinelaw.com/briefing/ect-alters-brain-networks-in-depression-new-insights-20260724-26179The Psychedelic Journalen2026-07-26T22:06:31.655417+00:00ECT Alters Brain Networks in Depression: New InsightsECT, brain networks, depression treatment, neuroimaging, functional connectivity, subcortical regions, default network, clinical research, therapeutic strategies, personalized treatmenthttps://mindmedicinelaw.com/briefing/evolutionary-theory-of-nightmares-and-clinical-implications-20260724-26167The Psychedelic Journalen2026-07-26T22:06:23.865984+00:00Evolutionary Theory of Nightmares and Clinical Implicationsevolutionary theory, nightmares, dream engineering, clinical interventions, neurocognitive mechanisms, emotional adaptation, threat rehearsal, pathological nightmares, adaptive dreaming, sleep disruptionhttps://mindmedicinelaw.com/briefing/phytochemicals-as-nmdar-inhibitors-potential-in-cns-therapeutics-20260724-26168The Psychedelic Journalen2026-07-26T22:06:17.480607+00:00Phytochemicals as NMDAR Inhibitors: Potential in CNS Therapeuticsphytochemicals, NMDAR inhibitors, neuroprotection, excitotoxicity, CNS therapeutics, neurodegenerative diseases, glutamate receptors, clinical trials, drug discovery, neuroinflammationhttps://mindmedicinelaw.com/briefing/doi-s-impact-on-cortical-network-modularity-in-mice-20260724-26169The Psychedelic Journalen2026-07-26T22:05:56.968941+00:00DOI's Impact on Cortical Network Modularity in MiceDOI, cortical network modularity, 5-HT2A receptor, thalamo-cortical interactions, psychedelic research, brain connectivity, calcium imaging, therapeutic applicationshttps://mindmedicinelaw.com/briefing/glun2d-modulators-and-ketamine-s-impact-on-gaba-and-ltp-20260724-26071The Psychedelic Journalen2026-07-26T15:05:20.092358+00:00GluN2D Modulators and Ketamine's Impact on GABA and LTPglun2d modulators, ketamine, GABA release, long-term potentiation, psychiatric treatment, NMDA receptor, synaptic plasticity, neural circuits, psychedelic research, clinical applicationshttps://mindmedicinelaw.com/briefing/loneliness-and-depression-implications-for-future-psychedelic-therapies-20260724-25852The Psychedelic Journalen2026-07-25T22:06:35.963718+00:00Loneliness and Depression: Implications for Future Psychedelic Therapiesloneliness, depression, psychedelic therapies, biopsychosocial mechanisms, clinical trials, mental health treatment, longitudinal study, inpatient treatment, biomarker analysis, social connectednesshttps://mindmedicinelaw.com/briefing/ipsc-study-unveils-shared-effects-of-rapid-acting-antidepressants-20260724-25804The Psychedelic Journalen2026-07-25T22:06:04.879603+00:00iPSC Study Unveils Shared Effects of Rapid-Acting AntidepressantsiPSC-derived neurons, rapid-acting antidepressants, treatment-resistant depression, psychedelics, molecular mechanisms, drug discovery, clinical trials, neuroscience, mental health, ketaminehttps://mindmedicinelaw.com/briefing/ssri-brexpiprazole-interaction-sexual-dysfunction-risks-20260723-25842The Psychedelic Journalen2026-07-25T22:06:42.671958+00:00SSRI-Brexpiprazole Interaction: Sexual Dysfunction RisksSSRI, brexpiprazole, sexual dysfunction, drug-drug interaction, antidepressants, antipsychotics, pharmacovigilance, 5-HT1A receptor, clinical implications, FAERS databasehttps://mindmedicinelaw.com/briefing/pilot-study-explores-personalized-dbs-for-schizophrenia-20260723-25854The Psychedelic Journalen2026-07-25T22:06:26.943037+00:00Pilot Study Explores Personalized DBS for Schizophreniapersonalized deep brain stimulation, treatment-resistant schizophrenia, intracranial circuit-guided DBS, salience network, brain network mapping, psychiatric disordershttps://mindmedicinelaw.com/briefing/evaluating-psilocybin-s-cardiac-safety-for-low-dose-use-20260723-25806The Psychedelic Journalen2026-07-25T22:06:20.409748+00:00Evaluating Psilocybin's Cardiac Safety for Low-Dose Usepsilocybin, cardiac safety, 5-HT2B receptor, low-dose therapy, mood disorders, valvular heart disease, exposure-response model, outpatient treatment, psilocin, clinical safetyhttps://mindmedicinelaw.com/briefing/esketamine-s-dual-role-in-bariatric-surgery-pain-and-mental-health-20260723-25857The Psychedelic Journalen2026-07-25T22:06:12.898103+00:00Esketamine's Dual Role in Bariatric Surgery: Pain and Mental Healthesketamine, bariatric surgery, opioid-free anesthesia, postoperative pain, mental health outcomes, clinical trials, pharmacokinetics, patient care strategies, perioperative risks, surgical recoveryhttps://mindmedicinelaw.com/briefing/discovery-psilocybin-and-amatoxins-co-occur-in-galerina-indica-20260722-25846The Psychedelic Journalen2026-07-26T15:05:55.915963+00:00Discovery: Psilocybin and Amatoxins Co-occur in Galerina Indicapsilocybin, amatoxins, Galerina indica, horizontal gene transfer, fungal biosynthesis, evolutionary biology, safety concerns, therapeutic use, ecological impact, fungal evolutionhttps://mindmedicinelaw.com/briefing/ketamine-s-extended-presence-in-neurons-implications-and-risks-20260722-25859The Psychedelic Journalen2026-07-26T15:05:46.628581+00:00Ketamine's Extended Presence in Neurons: Implications and Risksketamine, neuronal retention, brain function, therapeutic potential, long-term effects, clinical research, neurotoxicity, mental health treatmenthttps://mindmedicinelaw.com/briefing/dmt-detection-metal-doped-c20-fullerene-study-insights-20260722-25847The Psychedelic Journalen2026-07-26T15:05:38.673100+00:00DMT Detection: Metal-Doped C20 Fullerene Study InsightsDMT detection, C20 fullerene, metal doping, BeC19, computational study, drug sensing, quantum theory, clinical applications, forensic science, sensor developmenthttps://mindmedicinelaw.com/briefing/ketamine-abuse-and-sexual-health-implications-for-policy-20260722-26045The Psychedelic Journalen2026-07-26T15:05:29.284095+00:00Ketamine Abuse and Sexual Health: Implications for Policyketamine abuse, sexual health, public health policy, clinical guidelines, harm reduction, neuroscience, clinical trials, drug side effects, patient counseling, recreational drug usehttps://mindmedicinelaw.com/briefing/bacterial-dmt-production-breakthrough-in-scalable-synthesis-20260721-26148The Psychedelic Journalen2026-07-26T22:06:04.321243+00:00Bacterial DMT Production: Breakthrough in Scalable SynthesisDMT production, bacterial synthesis, Escherichia coli, tryptamine, methyltransferase, pharmaceutical applications, neuroscience research, clinical trials, psychedelic compounds, scalable productionhttps://mindmedicinelaw.com/briefing/s-ketamine-and-s-hnk-new-pathways-in-depression-treatment-20260721-26189The Psychedelic Journalen2026-07-26T22:05:49.361690+00:00S-ketamine and S-HNK: New Pathways in Depression TreatmentS-ketamine, S-HNK, depression treatment, neuroinflammation, TLR4 signaling, PPARα modulation, psychiatric disorders, clinical trials, antidepressant pathways, prefrontal cortexhttps://mindmedicinelaw.com/briefing/social-hierarchy-s-impact-on-ketamine-efficacy-in-mice-20260721-26076The Psychedelic Journalen2026-07-26T15:06:05.000730+00:00Social Hierarchy's Impact on Ketamine Efficacy in Micesocial hierarchy, ketamine response, chronic stress, mice study, personalized treatment, mental health, behavioral response, transcriptional response, psychiatric treatments, neuroscience